Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs BMS 906024 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 15 May 2017 Planned End Date changed from 1 Mar 2017 to 14 Jun 2017.
- 15 May 2017 Planned primary completion date changed from 1 Mar 2017 to 14 Jun 2017.